Active Filter(s):
Details:
Synedgen has developed a new class of glycopolymers with the ability to suppress inflammation, reduce infection, and improve healing at mucosal surfaces. The additional funding provides resources to optimize down-selection to a lead molecule to advance into animal studies.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Undisclosed
Partner/Sponsor/Collaborator: National Eye Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 29, 2020